Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
Riccardo Menandro, Pharmaceutical Scientific Reporter at Maven Pharma, shared on LinkedIn:
”Most conversations about lipid nanoparticles focus on the science.
This one focuses on the decisions.
LNP technology has moved from research platform to clinical mainstream faster than almost any other delivery system in recent memory.
Patisiran demonstrated hepatic gene silencing at therapeutic scale.
The COVID-19 vaccines demonstrated industrial scalability.
The pipeline now spans oncology, rare disease, hemophilia, and in vivo CRISPR editing.
But for organizations building or evaluating LNP-based programs, the scientific opportunity is only part of the picture.
Formulation expertise, IP position, tissue targeting strategy, and regulatory engagement are the variables that determine whether a program reaches the clinic on a competitive timeline, or doesn’t.
This white paper examines all four, with a focus on the decisions that matter most at the development planning stage.
Full document attached.”
Stay updated with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning